BOLD+interferon in the treatment of metastatic uveal melanoma: First report of active systemic therapy

Journal of Experimental and Clinical Cancer Research

Volumn 16, Issue 2, 1997, Pages 201-208

  Nathan, F E ^a,b   Berd, D ^a   Sato, T ^a   Shield, J A ^a   Shields, C L ^a   De Potter, P ^a   Mastrangelo, M J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemotherapy; Interferon; Melanoma; Uveal melanoma

Indexed keywords

ALPHA2B INTERFERON; BLEOMYCIN; DACARBAZINE; LOMUSTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MALE; METASTASIS; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; UVEA MELANOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; FEMALE; HUMANS; INTERFERON ALFA-2A; LOMUSTINE; LUNG DISEASES; MALE; MELANOMA; MIDDLE AGED; UVEAL NEOPLASMS; VINCRISTINE;

EID: 0030981749     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ameriean Cancer Soeiety: Cancer Facts & Figures 1993. 7, 1993.
2. Callender G. R., Wilder H.C., Ash J.E.: Five hundred melanomas of the choroid and ciliary body followed five years or longer. Am. J. Ophthalmol. 25: 962-967, 1942.
3. Wilder H.C., Paul E.V.: Malignant melanoma of the choroid and ciliary body: A study of 2,535 cases. Milit. Surg. 109: 370-375, 1951.
4. Paul E. V., Parnell B . L., Fraker M.: Prognosis of malignant melanoma of the choroid and ciliary body. Int. Ophthalmol. Clin. 2: 387-402, 1962.
5. Jensen O.A.: Malignant melanoma of uvea in Denmark 1943-1952. A clinical, histopathological, and prognostic study. Acta. Ophthalmol. (Suppl) 75: 128-152, 1963.
6. Jensen O.A.: Malignant melanomas of the human uvea: Recent follow-up of cases in Denmark, 1943-1952. Acta. Ophthalmol. 48: 1113-1128, 1970.
7. McLean I.W., Foster W.D., Zimmerman L.E.: Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch. Ophthalmol. 95: 48-58, 1977.
8. Raivio I.: Uveal melanomain Finland: An epidemiological, clinical, histological and prognostic study. Acta. Ophthalmol. S133: 5-63, 1977.
9. Einhorn L.H., Burgess M.A., Golllieb J.A.: Metastatic patterns of choroidal melanoma. Cancer 34: 1001-1004, 1974.
10. Bedikian A.Y., Kantarjian H., Young S.E., Body G.P.: Prognosis in metastatic choroidal melanoma. South. Med. J. 74: 574-577, 1981.
11. Rajpal S., Moore R., Karakousis C.P.: Survival in metastatic ocular melanoma. Cancer 52: 334-336, 1983.
12. Gragoudas E.S., Egan K.M., Seddon J.M., et al.: Survival of patients with metastases from uveal melanoma. Ophthalmology 98: 383-390, 1991.
13. Del Prete S.A., Maurer L.H., O'Donnell J., Forcier R.J., Le Marbre P.: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 68: 1403-1405, 1984.
14. McClay E.F., Mastrangelo M.J., Berd D., Bellet R.E.: Effective combination chemo/honnonal therapy for malignant melanoma: Experience with three consecutive trials. Int. J. Cancer 50: 553-556, 1992.
15. Fierro M.T., Bertero M., Novelli M., Appino A ., Doveil G.C., Colonna S., Bernengo M. G.: Therapy for metastatic melanoma: Effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Research 3: 127-131, 1993.
16. Reintgen D., Saba H.: Chemotherapy for stage 4 melanoma: A three-year experience with cisplatin, DTIC, BCNU, and tamoxifen. Seminars in Surgical Oncology 9: 251-255. 1993.
17. Crowell E.B.J., Higa G.M.: The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. West Virginia Medical Journal 89: 233-235, 1993.
18. Richards J.M., Gilewski T.A., Ramming K., Mitchel B., Doane L., Vogelelzang N.J.: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69: 427-429, 1992.
19. Berd D., Mastrangelo M.J.: Combination chemotherapy of metastatic melanoma (letter). J. Clin. Oncol. 13: 796, 1995.
20. Nathan F.E., Sato T., Hart E., Berd D., Mastrangelo M.J.: Response to combination chemotherapy of liver metastases from choroidal melanoma compared with cutaneous melanoma (abstr). Proc. Am. Soc. Clin. Oncol. 13: 394, 1994.
21. Pyrhönen S., Hahka-Kemppinen M., Muhonen T.: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J. Clin. Oncol. 10: 1919-1926, 1992.
22. Jules-Elysee K., White D.A.: Bleomycin-induced pulmonary toxicity. Clinics in Chest Medicine 11: 1-20, 1990.
23. Holoye P.Y., Luna M.A., MacKay B., Bedrossian C.W.M.: Bleomycin hypersensitivity pneumonitis. Ann. Intern. Med. 88: 47-49, 1978.
24. Blum R.H., Carter S.K., Agre K.: A clinical review of bleomycin - a new antineoplastic agent. Cancer 31: 903-913, 1973.
25. Bennett W.M., Pastore L., Houghton D.C.: Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat. Rep. 64: 921-924, 1980.
26. Perry D.J., Weiss R. B ., Taylor H.G.: Enhanced bleomycin toxicity during acute renal failure (letter). Cancer Treat. Rep. 66: 592-593, 1982.
27. McLeod B.F., Lawrence H.J., Smith D.W., Vogt P.J., Gandara D.R.: Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer 60: 2617-2620, 1987.
28. Aronin P.A., Mahaley M.S., Rudnick S.A., Dudka L., Donohue J.F., Selker R.G., Moore P.: Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: As assessment of risk factors. N. Engl. J. Med. 303: 183-188, 1980.
29. Nelson D.F., Schoenfeld D., Weinstein A.S., Nelson J.S., Wasserman T., Goodman R.L., Carabell S.: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; Preliminary results of an RTOG study. Radiation Oncology Biol. Phys 9: 1143-1151, 1983.
30. Weinstein A.S., Diener-West M., Nelson D.F., Pakuris E.: Pulmonary toxicityof carmustine in patients treated for malignant glioma. Cancer Treat. Rep. 70: 943-946, 1986.
31. Dent R.G.: Fatal pulmonary toxic effects of lomustine. Thorax 37: 627-629, 1982.
32. Stone M.D., Richardson M.G.: Pulmonary toxicity of lomustine. Cancer Treat. Rep. 71: 786-787, 1987.
33. Scigler H.F., Lucas V.S., Pickett N.J., Huang A.T.: DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 46: 2346-2348, 1980.
34. York R.M., Foltz A.T.: Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 61: 2183-2186, 1988.
35. Prudente Foundation Melanoma Study Group: Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer 63: 1676-1680, 1989.
36. D'Incalci M., Citti L., Taverna P., Catapano C.V.: Importance of the DNA repair enzyme 06-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat. Rev. 15: 279-292, 1988.
37. Aamdal S., Gerard B., Bohman T., D'Incalci M.: Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma - an effective combination with unexpected toxicity. Eur. J. Cancer 28: 447-450, 1992.
38. Gerard B., Aamdal S., Lee S.M., Leyvraz S., Lucas C., D'Incalci M., Bizzari J.P.: Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur. J. Cancer 29A: 711-719, 1993.
39. Kamisako T., Adachi Y., Chihara J., Yamamoto T.: Interstitial pneumonitis and interferon-alfa (letter). B.M.J. 306: 896, 1993.
40. Chin K., Tabata C., Sataka N., Nagai S., Moriyasu F., Kuno K.: P-neumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 105: 939-941, 1994.
41. Ogata K., Koga T., Yagawa K.: Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 106: 612-613, 1994.
42. Ikezoe J., Kohno N., Johkoh T., et al.: Pulmonary abnormalities caused by interferon with or without herbal drug: CT and radiographic findings. Nippon Igaku Hoshasen Gakkai Zasshi 55: 150-156, 1995.
43. Talpaz M., Kantarjian H.M., McCredie K.B., Keating M.J., Trujillo J., Gutterman J.: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280-1288, 1987.
44. Yufu Y., Yamashita S., Nishimura ., Nawata H., Hirata J.: Interstitial pneumonia caused by interferon-alpha in chronic myelogenous leukemia (letter). Am. J. Hematol. 47: 253, 1994.
45. Hahka-Kemppincn M., Muhonen T., Virolainen M., Jekunen A., Asko-Seljavaara S., Pyrhonen S.: Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Brit. J. Dermatol. 132: 973-977, 1995.
46. Mavligit G., Charnsangavi J. C., Carrasco H., Patt Y.Z., Benjamin R.S., Wallace S.: Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. J.A.M.A . 260: 974-976, 1988.